Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Panariello F, De Luca V, de Bartolomeis A.

Schizophr Res Treatment. 2011;2011:459284. doi: 10.1155/2011/459284.

2.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
3.

Atypical antipsychotic-induced weight gain: insights into mechanisms of action.

Roerig JL, Steffen KJ, Mitchell JE.

CNS Drugs. 2011 Dec 1;25(12):1035-59. doi: 10.2165/11596300-000000000-00000. Review.

PMID:
22133326
4.

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert M, Detraux J, van Winkel R, Yu W, Correll CU.

Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26. doi: 10.1038/nrendo.2011.156. Review.

PMID:
22009159
5.

Does levodopa accelerate the pathologic process in Parkinson disease brain?

Parkkinen L, O'Sullivan SS, Kuoppamäki M, Collins C, Kallis C, Holton JL, Williams DR, Revesz T, Lees AJ.

Neurology. 2011 Oct 11;77(15):1420-6. doi: 10.1212/WNL.0b013e318232ab4c.

PMID:
21917769
6.

A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.

Albaugh VL, Singareddy R, Mauger D, Lynch CJ.

PLoS One. 2011;6(8):e22662. doi: 10.1371/journal.pone.0022662.

7.

Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.

Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL.

J Clin Psychiatry. 2011 Sep;72(9):1270-6. doi: 10.4088/JCP.09m05933.

PMID:
21813076
8.

Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.

Gugger JJ.

CNS Drugs. 2011 Aug;25(8):659-71. doi: 10.2165/11591710-000000000-00000. Review.

PMID:
21790209
9.

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S.

Schizophr Res. 2010 Nov;123(2-3):225-33. doi: 10.1016/j.schres.2010.07.012. Review.

10.

MTHFR and risk of metabolic syndrome in patients with schizophrenia.

van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M.

Schizophr Res. 2010 Aug;121(1-3):193-8. doi: 10.1016/j.schres.2010.05.030.

PMID:
20547447
11.

Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia.

Padmavati R, McCreadie RG, Tirupati S.

Schizophr Res. 2010 Aug;121(1-3):199-202. doi: 10.1016/j.schres.2010.05.010.

PMID:
20538429
12.

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design.

Coccurello R, Moles A.

Pharmacol Ther. 2010 Sep;127(3):210-51. doi: 10.1016/j.pharmthera.2010.04.008. Review.

PMID:
20493213
13.

Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.

Hong CJ, Liou YJ, Bai YM, Chen TT, Wang YC, Tsai SJ.

Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.

PMID:
20375926
14.

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.

Reynolds GP, Kirk SL.

Pharmacol Ther. 2010 Jan;125(1):169-79. doi: 10.1016/j.pharmthera.2009.10.010. Review.

PMID:
19931306
15.

Effects of olanzapine and haloperidol on the metabolic status of healthy men.

Vidarsdottir S, de Leeuw van Weenen JE, Frölich M, Roelfsema F, Romijn JA, Pijl H.

J Clin Endocrinol Metab. 2010 Jan;95(1):118-25. doi: 10.1210/jc.2008-1815.

PMID:
19906788
16.

Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.

Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS.

Am J Psychiatry. 2009 May;166(5):583-90. doi: 10.1176/appi.ajp.2008.08081218.

17.

Atypical antipsychotic drugs and the risk of sudden cardiac death.

Ray WA, Chung CP, Murray KT, Hall K, Stein CM.

N Engl J Med. 2009 Jan 15;360(3):225-35. doi: 10.1056/NEJMoa0806994. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814.

18.

No interaction of body mass index and smoking on diabetes mellitus risk in elderly women.

Cullen MW, Ebbert JO, Vierkant RA, Wang AH, Cerhan JR.

Prev Med. 2009 Jan;48(1):74-8. doi: 10.1016/j.ypmed.2008.10.008.

19.

Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation.

Savoy YE, Ashton MA, Miller MW, Nedza FM, Spracklin DK, Hawthorn MH, Rollema H, Matos FF, Hajos-Korcsok E.

Schizophr Bull. 2010 Mar;36(2):410-8. doi: 10.1093/schbul/sbn104.

20.

Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease.

Scigliano G, Ronchetti G, Girotti F, Musicco M.

Parkinsonism Relat Disord. 2009 Feb;15(2):138-43. doi: 10.1016/j.parkreldis.2008.04.036.

PMID:
18556236
Items per page

Supplemental Content

Support Center